|Bid||0.000 x 400000|
|Ask||0.000 x 400000|
|Day's Range||16.665 - 16.745|
|52 Week Range||11.442 - 22.700|
|PE Ratio (TTM)||130.82|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.58|
HAMBURG, GERMANY / ACCESSWIRE / July 19, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of EUR 4 m to Evotec. Chronic cough is a major global health burden and has a significant impact on the quality of life of millions of people. Currently, no therapies are approved for the treatment of chronic cough.
On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.
On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.
HAMBURG, GERMANY / ACCESSWIRE / July 3, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. The transaction will result in a EUR 60 m upfront cash payment and a guaranteed financial commitment from Sanofi to Evotec for five years. Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives.
COMPANIES ARE AT THE FOREFRONT OF BETA CELL REPLACEMENT THERAPEUTIC RESEARCH FOR DIABETES EVOTEC RECEIVES EUR 3 MILLION PAYMENT FROM SANOFI MILESTONE FURTHER DEMONSTRATES ADVANCEMENT OF EVT INNOVATE INITIATIVE ...
Evotec AG (ETR:EVT), a life sciences company based in Germany, received a lot of attention from a substantial price increase on the XTRA over the last few months. As aRead More...
HAMBURG, GERMANY / ACCESSWIRE / June 20, 2018 / Evotec AG (FSE: EVT, XETRA: EVT) (ISIN:DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2018 with the required majorities. The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2017 were supported and approved.
HAMBURG, GERMANY / ACCESSWIRE / June 18, 2018 / Evotec AG (EVT.F) (EVT.DE) (ISIN:DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi's infectious disease unit into its organisation.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc ("Arix", London Stock Exchange: ARIX ) the Fred Hutchinson Cancer Research Center ("Fred Hutch"). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.
Arix Bioscience plc ("Arix", London Stock Exchange: ARIX) a global healthcare and life science company supporting medical innovation, today announced the formation of the LAB591, an academic "BRIDGE" collaboration with the Fred Hutchinson Cancer Research Center ("Fred Hutch") and Evotec AG ("Evotec", Frankfurt Stock Exchange: EVT). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Arix, Evotec and Fred Hutch plan to jointly select promising LAB591 research projects from the Fred Hutch labs.
Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines.
Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...
Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
After looking at Evotec AG’s (XTRA:EVT) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018.
Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated . Carna will access Evotec's INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application with the U.S.
Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany....
The latest earnings announcement Evotec AG’s (XTRA:EVT) released in December 2017 confirmed that the business endured a immense headwind with earnings declining by -11.89%. Below is a brief commentary onRead More...
Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.
Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited.
Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide.
Evotec AG announced today a strategic collaboration with Petra Pharma Corporation . Through the collaboration, Petra will access Evotec's INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application with the U.S.
Evotec AG (XTRA:EVT), a life sciences company based in Germany, saw a significant share price rise of over 20% in the past couple of months on the XTRA. With manyRead More...